Does the Clotting System Predict Outcomes in IPF?
Thrombosis, the formation of blood clots, is key to the initial stages of wound healing. But in some cases, clots form inside blood vessels and block blood flow, as in pulmonary embolus, a blood clot in the lung. Several studies have shown that people who have IPF are more likely to develop pulmonary emboli than others, but the exact mechanism behind this elevated risk remains unclear.
PAI-1Plasminogen Activator Inhibitor 1Thrombosis
Collard et al. published a study in 2010 that set out to determine the plasma biomarker profile of acute exacerbation of IPF and compare it to that of stable IPF and acute lung injury. They analyzed eight biomarkers, including PAI-1, in plasma from patients with stable IPF, acute exacerbation of IPF, and acute lung injury.
The authors found that PAI-1 levels were significantly higher in acute exacerbation of IPF compared with stable IPF. However, they found no correlation between clinical variables and levels of any of the eight biomarkers. The data did not demonstrate a clear association between plasma biomarker levels and survival in acute exacerbation of IPF, but the study was not designed to fully evaluate such a relationship. This leaves the door open for other studies to further explore a potential association.
Why are we studying this?
Evidence of Prognostic Value for PAI-1 was found in the following research:
Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis (Collard 2010)
Related Clinical Trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)